Michael Dickinson
@mike_dickinson1
Followers
2K
Following
1K
Statuses
1K
Haem/onc @Haem_pmcc_rmh in Melbourne. #Lymphoma Lead #CART Early phase trials. Lymphoma co-Chair @ALLGtrials Views are my own. #lymsm
Melbourne
Joined March 2009
RT @BloodJournal: The 2-year progression-free survival of 72% compares favorably with previously reported outcomes with chemoimmunotherapy…
0
27
0
Good news for patients with #DLBCL Diffuse large B-cell #lymphoma that #epcoritamab has received a positive funding recommendation from the PBAC in Australia. #lymsm 2L Axi-Cel this week, bispecifics in the 3L soon, it seems. Good news on a Friday.#lymsm
1
9
50
@PeterMacCC Great to see the dividends of Zuma-7, a trial we contributed to at Peter Mac, now available in Australia.
0
0
2
RT @PeterMacCC: More patients with aggressive blood cancers can now access subsidised CAR T-cell therapy thanks to a change to eligibility…
0
2
0
Indeed it was!!
What a joy it is to hear our very own @srpasricha presenting Best of #ASH24. Who else could personalise this so much and use a picture of the hallowed ground of the @MCG (Melbourne Cricket Ground) to such good effect? Go Santa!
0
0
9
Great to be at #ASH24. Cudos to @adrianminson for his @hsanz_org_au award and for his work on glofitamab as a 1L Rx for high risk DLBCL. No compromise on the chemo and remarkable 20m CR rate in very high burden #DLBCL #lymphoma #lymsm #glofitamab Thx to investigators in Oz!!
1
2
25
RT @DrChrisPFox: STARGLO Ph3 RCT - substantial OS benefit with glofitamab-GemOx for pts w rrLBCL unsuitable for ASCT. A new standard of car…
0
13
0
RT @DrGarethGregor1: Delighted to share the practice-changing #STARGLO study manuscript at @TheLancet today. Transplant-ineligible DLBCL sh…
0
23
0
RT @SnowdomeAU: Snowdome would like to congratulate Dr @AdrianMinson on being awarded a globally prestigious @ASH_hematology Distinguished…
0
3
0
RT @PeterMacCC: 📢 Exciting News from @ASH_hematology. Prof Andrew Roberts AM will become the first Australian to be Editor-in-Chief of AS…
0
1
0
RT @PeterMacCC: 𝐅𝐢𝐫𝐬𝐭 𝐢𝐧 𝐡𝐮𝐦𝐚𝐧 𝐭𝐫𝐢𝐚𝐥: “The need for new, accessible treatment options for patients with cancer is critical,” explains @mike…
0
4
0
RT @elizabeth_budde: Transformative work and new standard of care for newly diagnosed HL, led by our very own Alex Herrera @cityofhope
0
3
0
RT @MichaelDJain: 92% of patients in remission at 2 years in advanced Hodgkin lymphoma is astonishing
0
3
0
@rogerplevy @DrPaulyDeSantis @JCO_ASCO @LymphClinician @Haem_pmcc_rmh @PeterMacCC In my original tweet I was remiss not to thank the patients who participated in the trial. A huge and meaningful contribution.
1
0
3
The current landscape of frontline large B-cell lymphoma trials | Blood | highly recommended reading. #lymsm
1
23
69
@Eddie_Cliff @laura_korin In the occasional patient once per month. Yes allo makes sense but not possible for many.
1
0
2
RT @DrRaulCordoba: #Hematology Omission of #Radiotherapy in Primary Mediastinal B-Cell #Lymphoma #PMBCL: IELSG37 Trial Results | @JCO_ASCO…
0
3
0
RT @graham74GC: Nice data from Brinkman et al showing co-administration of anti-CD20 bispecific antibody with anti-CD19 CAR T-cells enhance…
0
12
0